2017

Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials

Jinyu Liu  
*Huazhong University of Science and Technology*

Dong Liu  
*Huazhong University of Science and Technology*

Juan Li  
*Huazhong University of Science and Technology*

Lan Zhu  
*Huazhong University of Science and Technology*

Chengliang Zhang  
*Huazhong University of Science and Technology*

*See next page for additional authors*

Follow this and additional works at: [https://digitalcommons.assumption.edu/sciences-student](https://digitalcommons.assumption.edu/sciences-student)

Part of the [Life Sciences Commons](https://digitalcommons.assumption.edu/sciences-student)

**Recommended Citation**

Liu, Jinyu; Liu, Dong; Li, Juan; Zhu, Lan; Zhang, Chengliang; Lei, Kai; Xu, Qiling; and You, Ruxu, "Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials" (2017). *Biological and Physical Sciences Department Student Works*. 1.  
[https://digitalcommons.assumption.edu/sciences-student/1](https://digitalcommons.assumption.edu/sciences-student/1)

This Article is brought to you for free and open access by the Biological and Physical Sciences Department at Digital Commons @ Assumption University. It has been accepted for inclusion in Biological and Physical Sciences Department Student Works by an authorized administrator of Digital Commons @ Assumption University. For more information, please contact digitalcommons@assumption.edu.
Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation: A Meta-Analysis of Randomized Controlled Trials

Jinyu Liu, Dong Liu, Juan Li, Lan Zhu, Chengliang Zhang, Kai Lei, Qiling Xu, Ruxu You

1 Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, 2 Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China, 3 Department of Biotechnology and Molecules, Assumption College, Worcester, Massachusetts, United States of America, 4 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

* youruxu2008@163.com

Abstract

Background
Conversion to everolimus is often used in kidney transplantation to overcome calcineurin inhibitor (CNI) nephrotoxicity but there is conflicting evidence for this approach.

Objectives
To investigate the benefits and harm from randomized clinical trials (RCTs) involving the conversion from CNI to everolimus after kidney transplantation.

Methods
Databases were searched up to March 2016. Two reviewers independently assessed trials for eligibility and quality, and extracted data. Results are expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI).

Results
Eleven RCTs, with a total of 1,633 patients, met the final inclusion criteria. Patients converted to everolimus had improved renal function at 1 year posttransplant with an estimated glomerular filtration rate (eGFR) of 5.36 mL/min per 1.73 m$^2$ greater than patients remaining on CNI (p = 0.0005) and the longer-term results (> 1 year) of renal function was identical to that of 1 year. There was not a substantial difference in graft loss, mortality, and the occurrence of adverse events (AEs) or serious AEs. However, the risks of acute rejection and trial termination due to AEs with everolimus are respectively 1.82 and 2.63 times greater than patients staying on CNI at 1 year posttransplant (p = 0.02, p = 0.03, respectively). Further, those patients who converted to everolimus had a substantially greater risk of anemia.
hyperlipidemia, hypercholesterolemia, hypokalemia, proteinuria, stomatitis, mouth ulceration, and acne.

Conclusions
Conversion from CNI to everolimus after kidney transplantation is associated with improved renal function in the first 5 years posttransplant but increases the risk of acute rejection at 1 year posttransplant and may not be well endured.

Introduction
Kidney transplantation is the treatment of choice for most patients with end-stage renal disease. Strategies to increase donor organ availability and to prolong the transplanted kidney’s survival have become priorities in kidney transplantation. Immunosuppressive therapy is essential and significant in this respect, nevertheless, but choosing the best suitable immunosuppressive therapy is still fairly complex. The calcineurin inhibitors (CNIs) are the principal components of immunosuppressive therapy after kidney transplantation and have made a major contribution to current long-term transplant outcomes[1, 2]. Meanwhile, tacrolimus has been recommended as a first-line agent for kidney transplantation recipients in kidney disease improving global outcomes (KDIGO) in 2009 [3]. However, CNIs are associated with a number of potentially serious side effects, including nephrotoxicity, diabetes, hypertension, and neurotoxicity that contribute to morbidity and mortality after transplantation [4–8]. Upon the fifth year, 90% of grafts revealed evidence of CNI-related lesions, and whereas early acute nephrotoxicity is typically reversible with CNI minimization; chronic lesions cannot be altered once initiated [5]. Furthermore, combined therapy with tacrolimus and mycophenolic acid may be associated with a particularly higher risk of BK infection [9], which is the significant and dangerous factor in the failure of the transplanted kidney. Therefore, diminishing or even eliminating CNI has become the focus of further optimization of immunosuppressive therapy in renal transplantation.

Everolimus (EVR), a mammalian target of the rapamycin inhibitor (mTORi), works 100 times greater than cyclosporin. It is part of a distinguished group of immunosuppressive drugs that have a divergent mode of action to that of CNIs even though they bind to the identical intracellular immunophilin as tacrolimus, namely, FKBP12. The mTORi/FKBP12 complex binds to and hinders the TORC1 complex, preventing proliferation of numerous cell types, such as T-lymphocytes, alloprimed B cells, and CD8 TAb-sup cells [10, 11]. The side effect profile of EVR is different from that of CNI and includes impaired wound healing, mouth ulcers, stomatitis, arthralgia, hyperlipidemia, and anemia [12–15]. The KDIGO instructions suggest that EVR should not be initiated prior to surgical wounds healing [3]. However, EVR may improve renal function and reduce the occurrence of malignancy, which makes it an attractive alternative to CNIs for maintenance therapy after kidney transplantation [16, 17], even though it does cause glomerular disease in some patients resulting in marked proteinuria [18]. A number of randomized controlled trials (RCTs) have examined the potential benefits of introducing EVR after kidney transplantation using a variety of protocols that differ with respect to the timing and mode of conversion to EVR, whether CNIs are eliminated or diminished, and in the level of baseline renal function at the time of EVR introduction. Such studies have provided conflicting results on the efficacy and side effect profile of EVR.
Up to now, there is no published work that systematically reviews EVR used as a maintenance therapy in renal transplant recipients. We undertook the meta-analysis of randomized controlled trials (RCTs) to systematically identify and summarize the current available evidence of the short- and long-term benefits and harm of conversion from CNI to EVR-based maintenance immunosuppression for kidney transplant recipients.

**Materials and Methods**

**Information Sources and Search Strategies**

A systematic literature search was performed using Pubmed/MEDLINE, OVID/EMBASE, and Cochrane Library covering the period from the inception of the database until March 2016 using a predefined algorithm (S1 Table) without language restrictions. References included in pertinent systematic reviews were also screened.

**Eligibility Criteria**

Every RCT examining the conversion from CNI to EVR-based maintenance immunosuppression in adult isolated kidney transplantation was assessed. Research was judged to be suitable if they examined sudden or slow conversion to EVR, in the initial or later kidney transplant recipients, regardless of the time posttransplantation and baseline renal function. Trials that were deemed suitable included those in which the intervention (conversion to EVR) and reference (CNI continuation) groups were administered more maintenance immunosuppression comprising antimetabolites (mycophenolate or azathioprine) and steroids. Observational and uncontrolled studies, those examining children, those in which the participants obtained other solid organs plus a renal transplantation, and animal trials were eliminated.

**Data Extraction**

Data removal was done separately by 2 investigators (Jinyu Liu and Ruxu You) and discrepancies were resolved by a third investigator (Juan Li). We documented data on trial characteristics and demographics, such as authors’ names, year published, journal’s name, sample size per-arm, population characteristics, indications, CNI dose, EVR characteristics (bolus and maintenance dose, mode of administration, timing of intervention, sudden stopping or tapering of prior immunosuppression) and length of the trial. The main meta-analysis result was renal function (estimated Glomerular Filtration Rate, eGFR) and secondary results were acute rejection, graft loss, patient survival and AEs. All of the results were investigated 1 year post-transplantation; long-term results, if available, were also investigated.

**Assessment of Methodological Quality**

The methodological quality of the included trials and the risk of bias were evaluated with elements from the Cochrane Collaboration’s tool for determining the risk of bias [19, 20]. The domains implemented in the current systematic review concerned randomization and allocation concealment (selection bias), blinding (performance and detection bias), loss to follow-up, and keeping to the intention-to-treat principle (attrition bias), selective reporting (reporting bias), and other biases. We decided to put forth the meta-analysis of every one of the studies while offering a synopsis of the risk of bias across trials.

**Data Synthesis and Statistical Analysis**

For every study we recovered, we computed the crude risk ratio (RR) estimates and corresponding 95% confidence intervals (CI) for the evaluated binary results (acute rejection, graft
Results

Description of Studies

We identified 3,129 possibly relevant references (PubMed, 673; Ovid, 1801; Cochrane Library, 643; and other sources, 12). After examining the titles and abstracts and eliminating identical publications, 67 possibly qualified articles were determined. Fifteen reports [22–36] of 11 trials, including a total of 1,633 randomized patients, were chosen for inclusion in the meta-analysis (Fig 1). One of these trials was available in abstract form only by Wolfgang et al 2012 [31]. Nine trials compared EVR to cyclosporine, and 2 trials compared EVR to CNI (cyclosporine or tacrolimus).

All of the incorporated studies were designed to determine the safety and efficacy of conversion from CNI to EVR in adult kidney transplant patients. Design characteristics, immunosuppression regimens, and reported results for every study are summarized in Table 1. The median sample size was 96 participants (interquartile range, 13–337), and the median treatment duration was 19.5 months (with a minimum of 6 months and a maximum of 60 months). All of the trials stated renal function, acute rejection, graft loss, patient survival, and AEs. GFR was estimated by Nankivell formula in 5 trails [24–27, 29–33], modification of diet in renal disease (MDRD) formula in 3 trails [22, 34, 35], and was unclear in 3 studies [23, 28, 36]. Early conversion to EVR (defined as ≤3 months after transplantation) was evaluated in 5 studies [22, 23, 25, 28, 30, 31], whereas 6 studies evaluated the late conversion to EVR [24, 26, 27, 31, 32–36]. There was a difference in baseline renal function, both within and between the trials, but most of the patients had mild or moderate renal dysfunction at the time of randomization.

Risk of Bias in Included Studies

The Cochrane Collaboration tool was implemented to evaluate the risk of bias (Fig 2 and S1 Fig). All trials were randomized, but 3 trials gave no indication of the allocation method used. Ten trials were open-label and only 1 trial reported blinding investigators [35]. Attrition was
adequately reported in 10 trials and was generally low (< 20%). Intention-to-treat analysis was confirmed for 6 trials and was unclear for the remaining 5 trials.

Assessed Outcomes and Evidence Synthesis

Renal function. Renal function was reported at 1, 2, 3, and 5 years after transplantation by 8, 5, 3 and 2 included studies, respectively. In the ITT analysis, patients converted to EVR had significantly better renal function at 1, 2, 3, and 5 years after transplantation compared to patients remaining on CNI [(MD, 5.36; 95% CI, 2.32–8.39; I², 51%), (MD, 6.91; 95% CI, 3.04–10.79; I², 32%), (MD, 6.65; 95% CI, 1.61–11.70; I², 53%), and (MD, 6.50; 95% CI, 2.38–10.63; I², 0%); Fig 3A]. When studies were stratified according to the time of conversion to EVR (early versus late conversion, defined as ≤ 3 months after transplantation), there was a statistically significant trend toward a more favorable GFR difference between EVR and CNI groups in the late conversion trials (MD, 9.42; 95% CI, 6.13–12.70; I², 0%) compared to the early conversion trials (MD, 3.65; 95% CI, 0.70–6.60; I², 27%), with reduction in heterogeneity (Fig 3B).
| Study ID | Study design | Time to conversion since transplant | Method of switching | Pre-conversion | Intervention | Comparator | CNI in the intervention arm after switching | GFR | Graft loss | Mortality | Acute rejection | AEs | follow up (m) |
|----------|--------------|------------------------------------|--------------------|----------------|--------------|------------|------------------------------------------|-----|-----------|-----------|----------------|-----|--------------|
| Wolfgang 2012 [31] | a prospective open-label multicenter RCT (N = 337) | 3 m | Unclear | CsA, EC-MPS, steroids | EVR: Target level (5–10ng/ml), EC-MPS, steroids (N = 171) | CsA, EC-MPS, steroids (N = 166) | Unclear | ✓ | ✓ | ✓ | ✓ | ✓ | 12 |
| Thibault 2016 [22] | a prospective multicenter open-label RCT (N = 13) | within 24 h | No conversion | No | EVR: Bolus (6mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 7) | CsA, EC-MPS, steroids (N = 6) | None | ✓ | ✓ | ✓ | ✓ | ✓ | 6 |
| Seckinger 2008 [35] | a prospective single-center RCT (N = 39) | 6 m | Tapered | CsA, MPA, steroids | EVR: Target level (6–10ng/ml), MPA, steroids (N = 20) | CsA, MPA, steroids (N = 19) | CsA | ✓ | ✓ | ✓ | ✓ | ✓ | 15 |
| Budde 2011 [33] | a prospective multicenter parallel-group RCT (N = 300) | 4.5 m | Tapered | CsA, EC-MP, steroids | EVR: Bolus (1.5mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 154) | CsA, EC-MPS, steroids (N = 146) | CsA | ✓ | ✓ | ✓ | ✓ | ✓ | 12 |
| Mjörnstedt 2012 [30] | an open-label multicenter RCT (N = 202) | 7 w | Abrupt | CsA, EC-MP, steroids | EVR: Bolus (3mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 102) | CsA, EC-MPS, steroids (N = 100) | None | ✓ | ✓ | ✓ | ✓ | ✓ | 12 |
| Rostaling 2015 [23] | a prospective open-label multicenter RCT (N = 194) | 3 m | Tapered | CsA, EC-MPS, steroids | EVR: Bolus (3mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 96) | CsA, EC-MPS, steroids (N = 98) | CsA | ✓ | ✓ | ✓ | ✓ | ✓ | 12 |
| Chadban 2014 [28] | a prospective multinational open-label RCT (N = 96) | 2 w | Tapered | CsA, MPA, steroids | EVR: Target level (8–12ng/ml), steroids (N = 48) | CsA, MPA, steroids (N = 47) | CsA | ✓ | ✓ | ✓ | ✓ | ✓ | 12 |
| Budde 2015 [27] | an open-label prospective parallel-group RCT (N = 93) | > 6m | Tapered | CsA or TaC, EC-MPS, steroids | EVR: Bolus (1.5mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 46) | CsA or TaC, EC-MPS, steroids (N = 47) | CsA or TaC | ✓ | ✓ | ✓ | ✓ | ✓ | 12 |
| Bemelman 2009 [94] | a prospective multicenter open-label RCT (N = 77) | 6 m | Tapered | CsA, MPS, steroids | EVR: Target AUC (12150 mg h/L), EC-MPS, steroids (N = 38) | CsA, MPS, steroids (N = 39) | CsA | ✓ | ✓ | ✓ | ✓ | ✓ | 24 |

(Continued)
To additionally confront heterogeneity for renal function at 1 year after conversion to EVR, sensitivity analyses were done using the estimating procedures of GFR. We performed sensitivity analysis excluding 2 trials [22, 35] that reported GFR estimates based on MDRD and a similar effect to the original meta analysis was observed (MD, 5.18; 95% CI, 2.07–8.30; I², 56%). We performed additional sensitivity analysis excluding 2 trials [19, 24] that did not specify just which methods used to estimate GFR and a similar effect to the original meta analysis was observed (MD, 6.30; 95% CI, 3.06–9.53; I², 42%). Further, meta-regression analyses taking into consideration the baseline GFR calculations revealed that the baseline renal function did not have a substantial impact on the difference in renal function between EVR and CNI groups 1 year posttransplantation.

Table 1. (Continued)

| Study ID     | Study design          | Time to conversion since transplant | Method of switching | Immunosuppressive dosing regime | Compressor  | GFR | Graft loss | Mortality | Acute rejection | AEs | follow up (m) |
|--------------|-----------------------|-------------------------------------|---------------------|-------------------------------|-------------|-----|-----------|-----------|----------------|-----|--------------|
| Holdaas 2011 [32]  | an open-label multicenter RCT (N = 250) | 6 m  | Tapered  | CsA or TaC, MPA, Aza, steroids | EVR: Target level (6–10ng/mL), MPA, Aza, steroids (N = 127) | CsA or TaC | ✓  | ✓  | ✓  | ✓  | ✓ | 24 |
| Kihm 2009 [36]  | a prospective single-center RCT (N = 32) | 12 m | Tapered  | CsA, MPA, steroids | EVR: Bolus (3mg/d), Target level (6–10ng/ml), MPA, steroids (N = 17) | CsA, MPA, steroids (N = 15) | CsA | ✓  | ✓  | ✓  | ✓  | ✓ | 24 |
| Budde 2012 [29]  | a prospective multicenter parallel-group RCT (N = 300) | 4.5 m | Tapered  | CsA, EC-MPS, steroids | EVR: Bolus (1.5mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 154) | CsA, EC-MPS, steroids (N = 148) | CsA | ✓  | ✓  | ✓  | ✓  | ✓ | 36 |
| Mjörnstedt 2015 [25]  | an open-label multicenter RCT (N = 202) | 7 w  | Abrupt  | CsA, EC-MPS, steroids | EVR: Bolus (3mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 102) | CsA, EC-MPS, steroids (N = 100) | None | ✓  | ✓  | ✓  | ✓  | ✓ | 36 |
| Budde (ZEUS) 2015 [24]  | a prospective multicenter parallel-group RCT (N = 300) | 4.5 m | Tapered  | CsA, EC-MPS, steroids | EVR: Bolus (1.5mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 154) | CsAEC-MPS steroids (N = 146) | CsA | ✓  | ✓  | ✓  | ✓  | ✓ | 60 |
| Budde (APOLLO) 2015 [26]  | an open-label prospective parallel-group RCT (N = 93) | >6 m  | Tapered  | CsA or TaC, EC-MPS, steroids | EVR: Bolus (1.5mg/d), Target level (6–10ng/ml), EC-MPS, steroids (N = 46) | CsA or TaC, EC-MPS, steroids (N = 47) | CsA or TaC | ✓  | ✓  | ✓  | ✓  | ✓ | 60 |

CsA, cyclosporine A; EVR, everolimus; TaC, tacrolimus; Aza, azathioprine; MPA, mycophenolic acid; CNI, calcineurin inhibitor; EC-MPS, enteric-coated mycophenolate sodium; GFR, glomerular filtration rate; AEs, adverse effects; RCT, randomized controlled trial; h, hour; m, month; w, week.

doi:10.1371/journal.pone.0170246.t001
Acute rejection. Every one of the included studies added to the meta-analysis examining the link between conversion from CNI to EVR and acute renal allograft rejection. Every one of the trials implemented the description of biopsy-proven acute rejection (BPAR), excluding the trial by Seckinger et al [35]. In contrast to CNI maintenance, conversion to EVR was linked with a greater risk of documented acute rejection 1 year posttransplantation (RR, 1.82; 95% CI, 1.11–2.99; $I^2$, 43%; Fig 4A). Analysis based on a definition of BPAR showed similar findings (RR, 1.91; 95% CI, 1.12–3.25; $I^2$, 50% for patients converted to EVR). However, patients converted to EVR had a similar risk of acute rejection compared with the patients remaining on CNI up to 2, 3, and 5 years after transplantation [(RR, 1.55; 95% CI, 0.35–6.82; $I^2$, 14%), (RR, 1.62; 95% CI, 0.67–3.92; $I^2$, 71%), and (RR, 1.85; 95% CI, 0.94–3.65; $I^2$, 0%); Fig 4A]. Moreover, we performed subgroup analysis between early conversion (between 0–3 months) and late conversion (> 3 months), and the subgroup analysis showed that early conversion to EVR compared to CNI maintenance was associated with a significantly higher risk of acute rejection up to 1 year after transplantation. In contrast, late conversion to EVR compared to CNI maintenance had a higher risk of acute rejection than CNI maintenance and it did not reach statistical significance (Fig 4B). In total, subgroup analyses did not show statistical heterogeneity among the 2 subgroups ($I^2$ = 0%, $p$ = 0.59).

Renal allograft loss and mortality. There were 3 trials [23, 28, 31] that added to the meta-analysis examining the link between conversion from CNI to EVR and renal allograft loss while in the 5 other trials [22, 27, 30, 33, 35], no renal allografts were lost up to the first year posttransplantation. Patients converted to EVR had a similar risk of graft loss compared with the patients remaining on CNI (RR, 1.43; 95% CI, 0.44–4.68; $I^2$, 37%; Fig 5). Overall, 6 (0.93%) patients in the EVR group and 4 (0.93%) patients in the CNI group lost their graft within the first year after transplantation. There was no significant difference for long-term graft loss as well.

Mortality up to 1 year posttransplantation was reported in 8 studies. Altogether, 4 (0.62%) patients in the EVR group and 6 (0.95%) patients in the CNI group died within the first year after transplantation. There were no distinctions in mortality among patients who converted...
**Fig 3.** A. Everolimus versus calcineurin inhibitor; mean GFR up to 1–5 years after transplantation stratified by study duration. B. Everolimus versus calcineurin inhibitor; mean GFR up to 1 year after transplantation stratified by time to conversion.

doi:10.1371/journal.pone.0170246.g003
Fig 4. A. Everolimus versus calcineurin inhibitor; any rejection up to 5 years after transplantation stratified by study duration. B. Everolimus versus calcineurin inhibitor; any rejection up to 1 year after transplantation stratified by time to conversion.

doi:10.1371/journal.pone.0170246.g004
to EVR and those who continued on CNI (RR, 0.70; 95% CI, 0.22–2.18; I², 0%; Fig 6A). Risk ratios (RRs) and heterogeneity were alike when studies were stratified based on the time of conversion to EVR (Fig 6B). There was no significant difference for long-term mortality as well.

**Treatment failure.** Five studies [27, 28, 30, 31, 33] reported treatment failure 1 year post-transplantation. Overall, 64 (18.19%) patients in the EVR group and 29 (8.43%) patients in the CNI group failed within the first year after transplantation. There were no differences in

| Study or Subgroup | Everolimus | CNI | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------|-----|--------|-----------------------------|-----------------------------|
| 1.5.1 one year    |            |     |        |                             |                             |
| Chadban 2014      | 0          | 49  | 47     | 0.19 [0.01, 3.90]            |                             |
| Klemens 2011      | 0          | 154 | 146    | Not estimable                |                             |
| Klemens 2015      | 0          | 46  | 47     | Not estimable                |                             |
| Mjörnstedt 2012   | 0          | 102 | 100    | Not estimable                |                             |
| Rostaing 2015     | 5          | 96  | 98     | 5.10 [0.61, 42.89]           |                             |
| Seckinger 2008    | 0          | 20  | 19     | Not estimable                |                             |
| Thibault 2016     | 0          | 7   | 6      | Not estimable                |                             |
| Wolfgang 2012     | 1          | 171 | 166    | 0.97 [0.06, 15.39]           |                             |
| Subtotal (95% CI) | 645        | 629 | 100.0% | 1.43 [0.44, 4.68]            |                             |

Total events: 6 4

Heterogeneity: CH² = 3.16, df = 2 (P = 0.21); I² = 37%

Test for overall effect: Z = 0.60 (P = 0.55)

1.5.2 Two years

| Study or Subgroup | Everolimus | CNI | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------|-----|--------|-----------------------------|-----------------------------|
| Bemelman 2009     | 0          | 38  | 39     | Not estimable                |                             |
| Holdaas 2011      | 4          | 127 | 123    | 0.48 [0.15, 1.57]            |                             |
| Kimh 2009         | 0          | 17  | 15     | Not estimable                |                             |
| Subtotal (95% CI) | 182        | 177 | 100.0% | 0.48 [0.15, 1.57]            |                             |

Total events: 4 8

Heterogeneity: Not applicable

Test for overall effect: Z = 1.21 (P = 0.23)

1.5.3 Three years

| Study or Subgroup | Everolimus | CNI | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------|-----|--------|-----------------------------|-----------------------------|
| Klemens 2012      | 2          | 154 | 146    | 0.95 [0.14, 6.64]            |                             |
| Mjörnstedt 2015   | 0          | 102 | 100    | Not estimable                |                             |
| Subtotal (95% CI) | 256        | 246 | 100.0% | 0.95 [0.14, 6.64]            |                             |

Total events: 2 2

Heterogeneity: Not applicable

Test for overall effect: Z = 0.05 (P = 0.96)

1.5.4 Five years

| Study or Subgroup | Everolimus | CNI | Weight | Risk Ratio M-H, Fixed, 95% CI | Risk Ratio M-H, Fixed, 95% CI |
|-------------------|------------|-----|--------|-----------------------------|-----------------------------|
| Klemens (APOLLO) 2015 | 3          | 46  | 47     | 3.07 [0.33, 28.40]           |                             |
| Klemens (ZEUS) 2015 | 4          | 154 | 146    | 1.26 [0.29, 5.55]            |                             |
| Subtotal (95% CI) | 200        | 193 | 100.0% | 1.70 [0.51, 5.70]            |                             |

Total events: 7 4

Heterogeneity: CH² = 0.42, df = 1 (P = 0.52); I² = 0%

Test for overall effect: Z = 0.86 (P = 0.39)

Test for subgroup differences: CH² = 2.56, df = 3 (P = 0.47); I² = 0%

Fig 5. Everolimus versus calcineurin inhibitor; graft loss within 5 years after transplantation stratified by study duration.

doi:10.1371/journal.pone.0170246.g005
Efficacy and Safety of Everolimus for Maintenance Immunosuppression of Kidney Transplantation

### Table A: Everolimus vs. CNI

| Study or Subgroup | Everolimus | CNI | Risk Ratio | Risk Ratio |
|------------------|------------|-----|------------|------------|
|                  | Events     | Total | Events     | Total | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| 1.3.1 One year   |            |       |            |       |        |                     |                     |
| Chadban 2014     | 0          | 49   | 1          | 47    | 21.6%  | 0.32 [0.01, 7.66]  |                     |
| Kiemens 2011     | 0          | 154  | 1          | 146   | 21.7%  | 0.32 [0.01, 7.70]  |                     |
| Kiemens 2015     | 1          | 46   | 1          | 47    | 13.9%  | 1.02 [0.07, 15.85] |                     |
| Mjömland 2012    | 2          | 102  | 1          | 100   | 14.2%  | 1.96 [0.18, 21.28] |                     |
| Rostaing 2015    | 0          | 96   | 0          | 98    | Not estimable |                     |                     |
| Seckinger 2008   | 0          | 20   | 0          | 19    | Not estimable |                     |                     |
| Thibault 2016    | 0          | 7    | 0          | 6     | Not estimable |                     |                     |
| Wolfgang 2012    | 1          | 171  | 2          | 166   | 28.6%  | 0.49 [0.04, 5.30]  |                     |
| Subtotal (95% CI)| 522        | 566  | 100.0%     | 0.70 [0.22, 2.18] |                     |
| Total events     | 4          | 6    |            |        |        |                     |                     |
| Heterogeneity:   | Chi² = 1.35, df = 4 (P = 0.85); I² = 0% |                     |                     |
| Test for overall | Z = 0.62 (P = 0.54) |                     |                     |

| 1.3.2 Two years  |            |       |            |       |        |                     |                     |
| Bemelman 2009    | 0          | 38   | 0          | 39    | Not estimable |                     |                     |
| Hoitaa 2011      | 3          | 127  | 0          | 123   | 100.0% | 6.78 [0.35, 129.94] |                     |
| Kihl 2009        | 0          | 17   | 0          | 15    | Not estimable |                     |                     |
| Subtotal (95% CI)| 182        | 177  | 100.0%     | 6.78 [0.35, 129.94] |                     |
| Total events     | 3          | 0    |            |        |        |                     |                     |
| Heterogeneity:   | Not applicable |                     |                     |
| Test for overall | Z = 1.27 (P = 0.20) |                     |                     |

| 1.3.3 Three years|            |       |            |       |        |                     |                     |
| Kiemens 2012     | 3          | 154  | 3          | 146   | 37.9%  | 0.65 [0.19, 4.62]  |                     |
| Mjömland 2015    | 2          | 102  | 5          | 100   | 62.1%  | 0.39 [0.08, 1.97]  |                     |
| Subtotal (95% CI)| 256        | 246  | 100.0%     | 0.60 [0.20, 1.82]  |                     |
| Total events     | 5          | 8    |            |        |        |                     |                     |
| Heterogeneity:   | Chi² = 0.59, df = 1 (P = 0.44); I² = 0% |                     |                     |
| Test for overall | Z = 0.90 (P = 0.37) |                     |                     |

| 1.3.4 Five years |            |       |            |       |        |                     |                     |
| Kiemens (APOLLO)2015 | 2       | 46   | 4          | 47    | 56.2%  | 0.51 [0.10, 2.68]  |                     |
| Kiemens (ZEUS)2015  | 4          | 154  | 3          | 146   | 43.8%  | 1.26 [0.29, 5.55]  |                     |
| Subtotal (95% CI)  | 209        | 193  | 100.0%     | 0.64 [0.29, 2.46]  |                     |
| Total events       | 6          | 7    |            |        |        |                     |                     |
| Heterogeneity:     | Chi² = 0.64, df = 1 (P = 0.42); I² = 0% |                     |                     |
| Test for overall   | Z = 0.32 (P = 0.75) |                     |                     |

Test for subarous differences: Chi² = 2.32, df = 3 (P = 0.51); I² = 0%

### Table B: Early vs. CNI

| Study or Subgroup | Early Conversion | CNI | Risk Ratio | Risk Ratio |
|------------------|------------------|-----|------------|------------|
|                  | Events  | Total | Events  | Total  | Weight | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| Chadban 2014     | 0       | 49   | 1       | 47    | 21.6%  | 0.32 [0.01, 7.66]  |                     |
| Mjömland 2012    | 2       | 102  | 1       | 100   | 14.2%  | 1.96 [0.18, 21.28] |                     |
| Rostaing 2015    | 0       | 96   | 0       | 98    | Not estimable |                     |                     |
| Thibault 2016    | 0       | 7    | 0       | 6     | Not estimable |                     |                     |
| Wolfgang 2012    | 1       | 171  | 2       | 166   | 28.6%  | 0.49 [0.04, 5.30]  |                     |
| Subtotal (95% CI)| 425     | 417  | 64.4%   | 0.76 [0.19, 3.03] |                     |
| Total events     | 3       | 4    |          |        |        |                     |                     |
| Heterogeneity:   | Chi² = 1.03, df = 2 (P = 0.60); I² = 0% |                     |                     |
| Test for overall | Z = 0.40 (P = 0.69) |                     |                     |

| 1.4.2 Late conversion | Early Conversion | CNI | Risk Ratio | Risk Ratio |
|-----------------------|------------------|-----|------------|------------|
| Kiemens 2011          | 0               | 154 | 1          | 146       | 21.7%  | 0.32 [0.01, 7.70]  |                     |
| Kiemens 2015          | 1               | 46  | 1          | 47        | 13.9%  | 1.02 [0.07, 15.85] |                     |
| Seckinger 2008        | 0               | 20  | 0          | 19        | Not estimable |                     |                     |
| Subtotal (95% CI)     | 220              | 212 | 35.6%     | 0.59 [0.06, 4.38] |                     |
| Total events          | 1               | 2   |            |          |        |                     |                     |
| Heterogeneity:        | Chi² = 0.30, df = 1 (P = 0.58); I² = 0% |                     |                     |
| Test for overall      | Z = 0.51 (P = 0.61) |                     |                     |

Total (95% CI) | 645 | 629 | 100.0% | 0.70 [0.22, 2.18] |                     |

Total events | 4 | 6 |          |                     |                     |

Heterogeneity: Chi² = 1.35, df = 4 (P = 0.85); I² = 0%

Test for overall effect: Z = 0.62 (P = 0.54)

Test for subgroup differences: Chi² = 0.04, df = 1 (P = 0.84), I² = 0%
treatment failure between patients converted to EVR and those remaining on CNI (RR, 1.74; 95% CI, 0.79–3.86; $I^2$, 67%).

**Adverse events.** Every one of the trials involved in the meta-analysis documented adverse events (AEs), although there were differences between studies in the nature and incidence of the reported adverse events. The main AEs involved in infection, blood and lymphatic system disorders, gastrointestinal disorders, metabolism and nutrition disorders, and the body as a whole-general disorders. Overall, 427 (94.05%) patients in the EVR group and 403 (90.77%) patients in the CNI group suffered 1 or more AEs within the first year after transplantation. There were no differences in the incidence of AEs or serious AEs between patients converted to EVR and those remaining on CNI [(RR, 1.04; 95% CI, 1.00–1.08; $I^2$, 0%), and (RR, 1.07; 95% CI, 0.96–1.21; $I^2$, 18%); Fig 7A and 7B]. However, the risk of study discontinuation due to AEs up to 1 year after transplantation was greater in patients converted to EVR than in patients remaining on CNI (RR, 2.63; 95% CI, 1.13–6.15; $I^2$, 69%).

![Fig 6. A. Everolimus versus calcineurin inhibitor; mortality up to 1–5 years after transplantation stratified by study duration. B. Everolimus versus calcineurin inhibitor; mortality up to 1 year after transplantation stratified by time to conversion.](doi:10.1371/journal.pone.0170246.g006)

![Fig 7. A. Everolimus versus calcineurin inhibitor; any adverse events up to 1 year after transplantation; B. Everolimus versus calcineurin inhibitor; any serious adverse events up to 1 year after transplantation.](doi:10.1371/journal.pone.0170246.g007)
Reported adverse events, along with RR estimates and 95% CI up to 1 year after transplantation, are summarized in Fig 8 and S2 Table. Compared with patients on CNI continuation, those converted to EVR had a substantially higher risk of anemia, hyperlipidemia, hypercholesterolemia, hypokalemia, proteinuria, stomatitis, mouth ulceration, acne and a nonstatistically significant trend toward a higher risk of thrombocytopenia. Nevertheless, patients converted to EVR had a lower risk of cytomegalovirus, BK virus, and urinary tract infection, diabetes mellitus, hypertriglyceridemia, malignancy, and cough; however, it did not reach statistical significance (Table 2).

As for long-term safety, we did not perform meta-analysis because there were too few trials within the same duration. The occurrence of AEs and serious AEs was similar in the EVR group versus the CNI group. The most recurrent AEs (>10%) were anemia, diarrhea, peripheral edema, proteinuria, mouth ulceration, pyrexia, urinary tract infection, upper respiratory
tract infection, increased serum creatinine, cough, rash, and acne; the first 5 were substantially elevated in the EVR group than the CNI group (p < 0.05). In addition, leukocyte and platelet counts were decreased and liver enzymes (aspartate aminotransferase and alanine aminotransferase) and lipids (total cholesterol and triglycerides) were substantially elevated in the EVR group versus the CNI group (p < 0.05). No AEs were documented less commonly in the EVR group with a statistical difference.

**Discussion**

The findings from this meta-analysis establish that conversion from CNI to EVR-based maintenance immunosuppression after kidney transplantation is associated with an increased eGFR (about 10%, p < 0.01) up to 5 years after transplantation. There were no substantial differences in efficacy results between the 2 groups except that recipients who converted to EVR had a higher risk of acute graft rejection up to 1 year after transplantation. In terms of safety and tolerability, results were subordinate in the EVR group in contrast to the CNI group.

In renal transplantation, chronic allograft nephropathy (CAN) continues to be the primary reason for graft loss[37, 38]. CAN is characterized by a gradual decline of renal function with interstitial fibrosis and tubular atrophy, which causes proteinuria, high blood pressure, and a gradual escalation in serum creatinine. GFR is the most commonly utilized marker for the decline in renal function. Further, scientists have proposed that early low-grade proteinuria could offer a different marker to GFR for future risk [39–41]. Two previous meta-analysis [14, 42] evaluated mTORi for primary immunosuppression of kidney transplant recipients and concluded that mTORi showed significantly lower serum creatinine and more improved eGFR than those treated with a CNI. In the present meta-analysis, every one of the RCTs were available for analysis on renal function with GFR as the main endpoint. Our analysis conducted that eGFR was significantly elevated in the EVR group versus the CNI controls: a mean difference of 5.36mL/min per 1.73m² (p = 0.0005) at 1 year and 6.50 mL/min per 1.73m² (p = 0.002) 5 years after transplantation. Given the observed marked heterogeneity (I², 51%) for trials reporting on the effect of EVR conversion on renal function at 1 year after transplantation.

| Adverse events                  | Incidence of adverse events (%) | p-Value |
|-------------------------------|---------------------------------|---------|
| **Everolimus**                | **CNI**                         |         |
| anemia                        | 13.92                           | 8.52    | 0.004 |
| hyperlipidemia                | 10.15                           | 5.23    | 0.006 |
| hypercholesterolaemia         | 11.11                           | 5.59    | 0.01  |
| hypokalaemia                  | 6.25                            | 1.63    | 0.02  |
| proteinuria                   | 8.55                            | 3.53    | 0.007 |
| stomatitis                    | 18.04                           | 1.94    | <0.00001 |
| mouth ulceration              | 15.38                           | 0.75    | <0.00001 |
| acne                          | 10.25                           | 1.63    | 0.0005|
| thrombocytopenia              | 5.12                            | 2.23    | 0.29  |
| cytomegalovirus               | 8.90                            | 11.59   | 0.11  |
| BK virus                      | 2.85                            | 4.88    | 0.14  |
| urinary tract infection       | 21.48                           | 25.61   | 0.27  |
| diabetes mellitus             | 4.92                            | 8.29    | 0.16  |
| hypertriglyceridaemia         | 2.16                            | 2.51    | 0.77  |
| malignancy                    | 5.62                            | 7.08    | 0.51  |
| cough                         | 6.97                            | 7.35    | 0.90  |

Table 2. Incidence of the most common adverse events up to 1 year after transplant.

doi:10.1371/journal.pone.0170246.t002
transplantation, caution is required with respect to the magnitude of the overall estimate for this outcome. Subgroup and sensitivity analyses reinforced the overall conclusion that conversion to EVR was associated with improved eGFR and eliminated heterogeneity as well. Nevertheless, those patients who converted to EVR had a substantially greater risk of proteinuria (8.55% vs 3.53%, p = 0.007) at 1 year after the transplant and 2 patients developed proteinuria >1,000 mg/day post-conversion to everolimus. Offset against the insistent eGFR advantage of conversion to everolimus, this risk would seem to be allowable but because patients with elevated urine protein (e.g. > 150 or > 500 g/day) at the time of conversion seem to be more susceptible to gradual proteinuria after conversion to EVR [43], the transition should be avoided or done with care.

It has been reported that conversion from CNI to mTORi increases the risk of acute rejection [16, 22]. The present meta-analysis showed that conversion to EVR is associated with a higher risk of acute rejection at 1 year after transplantation. However, there was a similar risk of long-term acute rejection (> 1 year). Since the risk for acute rejection is highest in the first 3 months after transplantation [3], we did subgroup analysis between early conversion (between 0 and 3 months) and late conversion (> 3 months). The subgroup analysis showed that early conversion to EVR compared to CNI maintenance was associated with a significantly higher risk of acute rejection up to 1 year after transplantation; in contrast, although late conversion had a higher risk of acute rejection, it did not reach statistical significance. The meta-analysis showed that late versus early conversion to EVR was associated with a trend toward better renal function and a lower risk of acute rejection at 1 year. According to the evidence, late transition may be the better advice. In the 8 trials, only 1 trial abruptly discontinued CNI, so the present analysis did not show a difference in acute rejection between the trials evaluating abrupt and tapered discontinuation of CNI. However, experience in liver transplantation suggests that tapered discontinuation is preferable, especially when EVR conversion is introduced within the first few months of transplantation [44].

Mammalian target of rapamycin inhibitors are associated with a number of well-described side effects [4, 13, 18] that may limit the ability of patients to tolerate them. Our analysis confirmed this, indicating that the risk of study discontinuation due to AEs after EVR conversion was 2.63 times that of the patients maintained on CNIs. Overall, there was a substantial risk of adverse events after conversion to EVR, and this represents a significant barrier for its utility in preserving renal function after kidney transplantation. It was reported that EVR may lead an increased risk of bone marrow suppression [42]. Our analysis showed that conversion to EVR had a significantly higher risk of anemia, and a higher risk of thrombocytopenia, and leukopenia with no significant difference. Therefore, the real harm of EVR-induced thrombocytopenia and leukopenia is unclear from these trials. In addition, our analyses showed that conversion to EVR is associated with an increased risk of hyperlipidemia and hypercholesterolemia, although the requirements for a new statin therapy was not different to patients maintained on CNI. Conversion to EVR significantly increased the risk of stomatitis by 9.30 times (p < 0.00001) and mouth ulceration by 20.51 times (p < 0.00001) than CNI, but the rate of infection was similar to that of patients on CNI maintenance. A significant drawback of treatment with mTORi is the development of proteinuria which may reach the nephrotic range, especially after exposure to high everolimus concentrations [45]; our analysis confirmed the association between EVR and proteinuria, although the reported proteinuria levels were usually mild or less often moderate. We were unable to confirm any benefit in reduced malignancy in these 11 randomized trials, although this has been suggested by other data [46, 47]. The main limitation of this review is that of the contributory trials. Additionally, where graft-focused outcomes were well reported, many of the potentially informative patient-focused adverse outcomes were not reported, not defined, or inconsistently reported.
A longitudinal cohort study included 9,353 kidney transplant recipients showed that mTORi use was associated with a higher risk of all-cause mortality but not allograft loss [48]. The majority of RCTs included in our meta-analysis were not powered to detect a difference in graft or patient survivals, and the true effect of EVR conversion on graft and patient outcomes is still to some extent uncertain. This is especially the case for long-term outcomes, although there are 6 trials included in the meta-analysis reported outcomes beyond 1 year, they scatter in different time periods. As to long-term safety, there are too few studies to perform a meta-analysis. This review focuses on the requirement for follow-up of clinical studies in transplantation to go well beyond the immediate term to 5 years and beyond. This has been shown in renal transplantation in which a coordinated effort between the researchers and a registry of long-term patient follow-up of up to 15 years posttransplantation [49].

There are further possible restrictions in the current meta-analysis. First, we did not incorporate any unpublished evidence, so there may be publication bias in the meta-analysis. Second, even though randomized evidence is safeguarded from selection bias, performance and detection biases could be possible confounders. An approach toward addressing this would be to exempt open-label trials. Ultimately, the majority of the incorporated trials were, by necessity, open-label trials, and so trial exclusion was not a viable choice. Lastly, a group of study parameters could possibly impede our study outcomes. The variation in baseline renal function between studies, and the unmistakable patient characteristics inside separate studies may have added to the noted heterogeneity.

Conclusion
The currently available randomized evidence indicates that conversion from CNI to EVR after kidney transplantation is associated with short and long-term improvements in GFR in a number of studies, but these findings must be balanced against the greater rates of proteinuria, discontinuation due to AEs, and higher incidences of acute rejection up to 1 year posttransplant with the use of EVR as compared with CNI. Moreover, late conversion to EVR might be associated with a trend toward better renal function and a lower risk of acute rejection up to 1 year posttransplantation than early conversion. Additionally, in deciding the optimal immunosuppression strategy for their patients, clinicians should be alert to the increased risk of bone marrow suppression, dyslipidemia, mouth ulceration, and stomatitis after conversion to EVR which, however, has no effect on graft and patient survival.

Supporting Information
S1 Fig. Risk of bias summary: each risk of bias item for each included study.
(TIF)
S2 Fig. Funnel plot of pooled efficacy and safety of everolimus comparing with calcineurin inhibitor.
(TIF)
S1 Table. Literature search algorithm.
(DOCX)
S2 Table. Effect estimate of all outcomes.
(DOCX)
S3 Table. PRISMA checklist.
(DOC)
Acknowledgments
This research was funded by Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (Grant No. 2016A016).

Author Contributions

Conceptualization: JYL DL JL LZ CLZ KL QLX RXY.
Data curation: JYL JL CLZ.
Formal analysis: JYL KL QLX.
Funding acquisition: JYL.
Investigation: JYL JL RXY.
Methodology: JYL DL RXY.
Project administration: JYL DL JL.
Resources: JYL CLZ RXY.
Software: JYL KL QLX.
Supervision: DL LZ RXY.
Validation: JYL LZ RXY.
Visualization: JYL RXY.
Writing – original draft: JYL.
Writing – review & editing: QLX RXY.

References

1. Liu JY, You RX, Guo M, Zeng L, Zhou P, Zhu L, et al. Tacrolimus versus cyclosporine as primary immunosuppressants after renal transplantation: A Meta-Analysis and economics evaluation. Am J Ther. 2016; 23(3): e810–e824. doi: 10.1097/MJT.0000000000000150 PMID: 25299636
2. Riella LV, Gabardi S, Azzi J. Belatacept and Long-Term outcomes in kidney transplantation. N Engl J Med. 2016; 374(26): 2599–2600.
3. SURGEONS OJOT. Kidney disease improving global outcomes (KDIGO) clinical practise guideline for the care of kidney transplantation receipts. American Journal of transplantation. 2009; 9(Suppl 3): 131–155.
4. Almeida C, Silveira M, de Araújo V, de Lemos L, de Oliveira Costa J, Reis C, et al. Safety of immunosuppressive drugs used as maintenance therapy in kidney transplantation: A systematic review and Meta-Analysis. Pharmaceuticals. 2013; 6(10): 1170–1194. doi: 10.3390/ph6101170 PMID: 24275847
5. Nankivell BJ, Borrow RJ, Fung CLS, O'Connell PJ, Chapman JR, Allen RDM. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation. 2004; 78(4): 557–565. PMID: 15446315
6. Nankivell BJ, P'Ng CH, O'Connell PJ, Chapman JR. Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology. Transplantation. 2016; 100(8): 1723–1731. doi: 10.1097/TP.0000000000001243 PMID: 27308929
7. Borda B, Lengyel C, Várkonyi T, Kemény É, Ottlakán A, Kubik A, et al. Side effects of the calcineurin inhibitor, such as new-onset diabetes after kidney transplantation. Acta Physiologica Hungarica. 2014; 101(3): 388–394. doi: 10.1556/APhysiol.101.2014.3.13 PMID: 25183511

8. Chapman JR. Chronic calcineurin inhibitor Nephrotoxicity-Lest we forget. American Journal of Transplantation. 2011; 11(4): 693–697. doi: 10.1111/j.1600-6143.2011.03504.x PMID: 21446974

9. Suwelack B, Malvar Y, Koch M, Sester M, Sommerer C. The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev (Orlando). 2012; 26(3): 201–211.

10. Sanchez-Fructuoso AI. Everolimus: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2008; 4(6): 807–819. doi: 10.1517/17425255.4.6.807 PMID: 18611120

11. Avila CL, Zimmerer JM, Elzein SM, Pham TA, Abdel-Rasoul M, Bumgardner GL. mTOR Inhibition suppresses posttransplant alloantibody production through direct inhibition of alloprimed b cells and sparing of CD8+ Antibody-Suppressing t cells. Transplantation. 2016; 100(9): 1898–1906. doi: 10.1097/TP.0000000000001291 PMID: 27362313

12. Zaza G, Tomei P, Ria P, Granata S, Boschierno L, Lupò A. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors. Clin Dev Immunol. 2013; 2013: 403280. doi: 10.1155/2013/403280 PMID: 24151517

13. Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant. 2010; 24(2): 149–156. doi: 10.1111/j.1399-0012.2010.01232.x PMID: 20236129

14. Bin W, Feng-bo W, J L, Lei Y, Yao T. Meta-analysis of immunosuppressive therapy with target-of-rapamycin inhibitor instead of calcineurin inhibitor after kidney transplantation operation. China Pharmacy. 2011; 22(34): 3229–3231.

15. Glover TE, Watson CJE, Gibbs P, Bradley JA, Ntzani EE, Kosmopoulos V. Conversion from Calcineurin to mTOR inhibitors in liver transplantation. Transplantation. 2016; 100(3): 621–629. doi: 10.1097/TP.0000000000001006 PMID: 26636736

16. Lim WH, Eris J, Kanellis J, Pussell B, Wiid Z, Witcombe D, et al. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors in maintenance immunosuppression in kidney transplant recipients. Am J Transplant. 2014; 14(9): 2106–2119. doi: 10.1111/ajt.12795 PMID: 25088685

17. Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 2009; 20(12): 2493–2502. doi: 10.1681/ASN.2009111186 PMID: 19875810

18. Diekmann F, Andres A, Oppenheimer F. mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev (Orlando). 2012; 26(1): 27–29.

19. Higgins JPT, Altman DG, Gotzsche PC, Jueni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj-Brit Med J. 2011; 343: d5928.

20. Savovic J, Weeks L, Sterne JAC, Turner L, Altman DG, Moher D, et al. Evaluation of the Cochrane Collaboration’s tool for assessing the risk of bias in randomised trials: Focus groups, online survey, proposed recommendations and their implementation. Systematic reviews. 2014; 3: 37. doi: 10.1186/2046-4053-3-37 PMID: 24731537

21. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ. 2009; 339: b2700. doi: 10.1136/bmj.b2700 PMID: 19622552

22. Thibault G, Painaud G, Legendre C, Merville P, Coulon M, Chasseuil E, et al. CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. Transpl Int. 2016; 29(2): 184–195. doi: 10.1002/tr.12688 PMID: 25088685

23. Rostaing L, Hertig A, Albano L, Anglicheau D, Durrbach A, Vuiblet V, et al. Fibrosis progression according to Epithelial-Mesenchymal transition profile: A randomized trial of everolimus versus CsA. Am J Transplant. 2015; 15(5): 1303–1312. doi: 10.1111/ajt.13132 PMID: 25809694

24. Budde K, Lehner F, Sommerer C, Reinke P, Arns W, Eisenberger U, et al. Five-Year outcomes in kidney transplant patients converted from cyclosporine to everolimus: The randomized ZEUS study. Am J Transplant. 2015; 15(1): 119–128. doi: 10.1111/ajt.12952 PMID: 25521535

25. Mjornstedt L, Schwartz SS, von Zur MB, Jespersen B, Hansen JM, Bistrup C, et al. Renal function three years after early conversion from a calcineurin inhibitor to everolimus: Results from a randomized trial in kidney transplantation. Transpl Int. 2015; 28(1): 42–51. doi: 10.1111/tri.12437 PMID: 25176389
26. Budde K, Sommerer C, Rath T, Reinke P, Haller H, Witzke O, et al. Renal function to 5 years after late conversion of kidney transplant patients to everolimus: A randomized trial. J Nephrol. 2015; 28(1): 115–123. doi: 10.1007/s10046-014-1344-4 PMID: 25192833

27. Budde K, Rath T, Sommerer C, Haller H, Reinke P, Witzke O, et al. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: The randomized APOLLO study. Clin Nephrol. 2015; 83 (01): 11–21.

28. Chadban SJ, Eris JM, Kanelis J, Pilmore H, Lee PC, Lim SK, et al. A randomized, controlled trial of everolimus-based dual immunosuppression versus standard of care in de novo kidney transplant recipients. Transpl Int. 2014; 27(3): 302–311. doi: 10.1111/tri.12252 PMID: 24279685

29. Budde K, Lehner F, Sommerer C, Arns W, Reinke P, Eisenberger U, et al. Conversion From Cyclosporine to Everolimus at 4.5 Months Posttransplantation: 3-Year Results From the Randomized ZEUS Study. Am J Transplant. 2012; 12(6): 1528–1540. doi: 10.1111/j.1600-6143.2012.03994.x PMID: 22642473

30. Mjörnstedt L, Sørensen SS, von Zur Mühlen B, Jespersen B, Hansen JM, Bstrup C, et al. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: A randomized trial in kidney transplantation. Am J Transplant. 2012; 12(10): 2744–2753. doi: 10.1111/j.1600-6143.2012.04162.x PMID: 22912414

31. Arns W. SCWOH H. SMJJK. Efficacy and Safety of Three Different Treatment Regimens in de Transplantation. 2012; 94(Suppl 10): S995.

32. Hallvard Holdaas LRDS, Erik H, Strøm AJKM, Connell APJO, Investigators OBOT. Conversion of Long-Term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A Randomized, multicenter, 24-Month study. Transplantation. 2011; 92(4): 410–418. doi: 10.1097/TP, 0b013e31821c12c6 PMID: 21697773

33. Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. The Lancet. 2011; 377(9768): 837–847.

34. Bemelman FJ, de Maar EF, Press RR, van Kan HJ, Ten Berge IJ, Homan Van Der Heide JJ, et al. Mini-Analysis of randomized trials. Transplantation. 2006; 81(9): 1234–1248. doi: 10.1097/01.tp.0000219703.39149.85 PMID: 16699448

35. Seckinger J, Sommerer C, Hinkel U, Hoffmann O, Zeier M, Schwenger V. Switch of immunosuppression from cyclosporine a to everolimus: Impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens. 2008; 26(11): 2213–2219. doi: 10.1097/HJH.0b013e32830e940 PMID: 18954763

36. Kim LP, Hinkel U, Michael K, Sommerer C, Seckinger J, Morath C, et al. Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine a to everolimus. Transplantation. 2009; 88(2): 421–428. doi: 10.1097/TP.0b013e3181af1d6 PMID: 19667948

37. Grinyo JM, Saval N, Campistol JM. Clinical assessment and determinants of chronic allograft nephropathy in maintenance renal transplant patients. Nephrology Dialysis Transplantation. 2011; 26(11): 3750–3755.

38. CHAPMAN JR. Longitudinal analysis of chronic allograft nephropathy: Clinicopathologic correlations. Kidney International. 2005; 68(Suppl 99): 108–112.

39. Cantarovich F, Martinez F, Heguilen R, Thervet E, Mamzer-Bruneel MF, Gonzalez C, et al. Proteinuria &gt;0.5 g/d, a prevalent prognostic factor for patient and graft survival in kidney transplantation. Clinical Transplantation. 2010; 24(2): 175–180. doi: 10.1111/j.1399-0012.2009.01043.x PMID: 19624694

40. Sancho CA, Pallardo ML, Avila BA, Gavela ME, Beltran CS, Crespo AJ. Very low-grade proteinuria at 3 months posttransplantation is an earlier marker of graft survival. Transplant Proc. 2009; 41(6): 115–123. doi: 10.1016/j.transproceed.2009.06.005 PMID: 19623023

41. Halimi JM, Laoud I, Buchler M, Al-Najjar A, Chatellet V, Houssaint TS, et al. Early low-grade proteinuria: Causes, short-term evolution and long-term consequences in renal transplantation. American Journal of Transplantation. 2005; 5(9): 2281–2288. doi: 10.1111/j.1600-6143.2005.01020.x PMID: 16096510

42. Webster AC, Lee VWS, Chapman JR, Craig JC. Target of rapamycin inhibitors (Sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and Meta-Analysis of randomized trials. Transplantation. 2006; 81(9): 230–234. doi: 10.1097/01.tp.0000219703.39149.85 PMID: 16699448

43. Sanchez-Fructuoso AI, Ruiz JC, Calvo N, Rodrigo E, Perez-Flores I, Gomez-Alamillo C, et al. Everolimus as primary immunosuppression in kidney transplantation: Experience in conversion from calcineurin inhibitors. Transplantation. 2012; 93(4): 398–405. doi: 10.1097/TP.0b013e31823fd0e PMID: 22245871

44. Fischer L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver
transplantation—PROTECT. Am J Transplant. 2012; 12(7): 1855–1865. doi: 10.1111/j.1600-6143.2012.04049.x PMID: 22494671

45. Loriga G, Ciccarese M, Pala PG, Satta RP, Fanelli V, Manca ML, et al. De novo Everolimus-Based therapy in renal transplant recipients: Effect on proteinuria and renal prognosis. Transpl P. 2010; 42(4): 1297–1302.

46. Opelz G, Unterrainer C, Susal C, Dohler B. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients. Nephrol Dial Transplant. 2016; 31(8): 1360–1367. doi: 10.1093/ndt/gfw088 PMID: 27190384

47. Miura M, Yanai M, Fukasawa Y, Higashiya H, Ito Y. De novo proteinuria with pathological evidence of glomerulonephritis after everolimus induction. Nephrology. 2014; 19(Suppl 3): S57–S59.

48. Badve SV, Pascoe EM, Burke M, Clayton PA, Campbell SB, Hawley CM, et al. Mammalian target of rapamycin inhibitors and clinical outcomes in adult kidney transplant recipients. Clin J Am Soc Nephrol. 2016 Jul 21. pii: CJN.00190116.

49. Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-Year results. Transplantation. 2004; 78(11): 1653–1660. PMID: 15591955